Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species
- PMID: 15956404
- PMCID: PMC1151899
- DOI: 10.1128/JCM.43.6.2824-2829.2005
Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species
Abstract
The lipophilic yeast Malassezia is an exacerbating factor in atopic dermatitis (AD) and colonizes the skin surface of patients with AD. With the goal of reducing the number of Malassezia cells, we investigated the antifungal activities of a therapeutic agent for AD, tacrolimus, and the azole agents itraconazole and ketoconazole against Malassezia species in vitro. We examined 125 strains of the 11 currently accepted Malassezia species by using the agar dilution method. All strains of the 11 Malassezia species were very susceptible to both azole agents, with MICs ranging from 0.016 to 0.25 mug/ml. Tacrolimus had antifungal activities against half of the strains, with MICs ranging from 16 to 32 mug/ml. Two of the major cutaneous floras, Malassezia globosa and Malassezia restricta, have several genotypes in the intergenic spacer region of the rRNA gene; the azole agents had slightly higher MICs for specific genotype strains of both microorganisms. A combination of azole agents and tacrolimus had a synergistic effect against Malassezia isolates, based on a fractional inhibitory index of 0.245 to 0.378. Our results provide the basis for testing these agents in future clinical trials to reduce the number of Malassezia cells colonizing the skin surface in patients with AD.
Figures


Similar articles
-
Molecular epidemiology, in vitro susceptibility and exoenzyme screening of Malassezia clinical isolates.J Med Microbiol. 2020 Mar;69(3):436-442. doi: 10.1099/jmm.0.001161. J Med Microbiol. 2020. PMID: 32068525
-
Non-synonymous ERG11 mutations in M. restricta and M. arunalokei: impact on azole susceptibility.Microbiol Spectr. 2025 Jun 3;13(6):e0000725. doi: 10.1128/spectrum.00007-25. Epub 2025 May 15. Microbiol Spectr. 2025. PMID: 40372034 Free PMC article.
-
Antifungal activities of azole agents against the Malassezia species.Int J Antimicrob Agents. 2007 Mar;29(3):281-4. doi: 10.1016/j.ijantimicag.2006.09.016. Epub 2007 Jan 16. Int J Antimicrob Agents. 2007. PMID: 17223320
-
[Genotype analysis of the rRNA gene of Malassezia colonizing the skin surface of patients with atopic dermatitis].Nihon Ishinkin Gakkai Zasshi. 2005;46(3):147-50. doi: 10.3314/jjmm.46.147. Nihon Ishinkin Gakkai Zasshi. 2005. PMID: 16094286 Review. Japanese.
-
[Malassezia species in patients with seborrheic dermatitis and atopic dermatitis].Nihon Ishinkin Gakkai Zasshi. 2005;46(3):163-7. doi: 10.3314/jjmm.46.163. Nihon Ishinkin Gakkai Zasshi. 2005. PMID: 16094289 Review. Japanese.
Cited by
-
Azole Antifungal Sensitivity of Sterol 14α-Demethylase (CYP51) and CYP5218 from Malassezia globosa.Sci Rep. 2016 Jun 13;6:27690. doi: 10.1038/srep27690. Sci Rep. 2016. PMID: 27291783 Free PMC article.
-
Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients.J Korean Med Sci. 2007 Oct;22(5):868-72. doi: 10.3346/jkms.2007.22.5.868. J Korean Med Sci. 2007. PMID: 17982237 Free PMC article. Clinical Trial.
-
Genomic Multiplication and Drug Efflux Influence Ketoconazole Resistance in Malassezia restricta.Front Cell Infect Microbiol. 2020 Apr 30;10:191. doi: 10.3389/fcimb.2020.00191. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32426297 Free PMC article.
-
Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment.Ann Dermatol. 2015 Oct;27(5):523-30. doi: 10.5021/ad.2015.27.5.523. Epub 2015 Oct 2. Ann Dermatol. 2015. PMID: 26512166 Free PMC article.
-
Antifungal Resistance Regarding Malassezia pachydermatis: Where Are We Now?J Fungi (Basel). 2020 Jun 25;6(2):93. doi: 10.3390/jof6020093. J Fungi (Basel). 2020. PMID: 32630397 Free PMC article. Review.
References
-
- Back, O., A. Scheynius, and S. G. Johansson. 1995. Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. Arch. Dermatol. Res. 287:448-451. - PubMed
-
- Berenbaum, M. C. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130. - PubMed
-
- Cruz, M. C., A. L. Goldstein, J. Blankenship, M. Del Poeta, J. R. Perfect, J. H. McCusker, Y. L. Bennani, M. E. Cardenas, and J. Heitman. 2001. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob. Agents Chemother. 45:3162-3170. - PMC - PubMed
-
- Del Poeta, M., M. C. Cruz, M. E. Cardenas, J. R. Perfect, and J. Heitman. 2000. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:739-746. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources